Houston Business Journal (Internet / Print) 05/29/06 http://www.bizjournals.com/houston/stories/2006/05/29/story3.html?page=2 Houston-based CytoGenix Inc. is flying high after landing a contract for its synthetic DNA-based vaccine to be used in testing against the avian flu. The biochemical company will work with The University of Texas Medical Branch at Galveston on preclinical animal studies of its synDNA H5N1 vaccine against a known strain of H5N1. In preparation of a possible bird flu pandemic, the synDNA technology is designed to produce millions of doses of a DNA vaccine over a period of a few months. As part of the UTMB deal, CytoGenix will sponsor research undertaken by university scientists to test its DNA vaccines against their strains of avian flu. The work will be performed in UTMB's new Biosafety Level 4 lab, which is one of only four of its kind currently operating in the United States.